Inhibikase Therapeutics, Inc. (IKT) Earning

NASDAQ Currency in USD Disclaimer

$2.96

south_east -$0 (0%)
Day's range
$2.92
Day's range
$3.05

Inhibikase Therapeutics, Inc. Analyst EPS Estimates

Quarter Number of Estimates Low Estimate High Estimate Average Estimate
Q1 2024 1 -$0.67 -$0.67 -$0.67
Q2 2024 1 -$0.48 -$0.48 -$0.48
Q3 2024 2 -$0.09 -$0.08 -$0.09
Q1 2025 1 -$0.11 -$0.11 -$0.11
Q2 2025 1 -$0.12 -$0.12 -$0.12
Q3 2025 1 -$0.14 -$0.14 -$0.14
Q4 2025 1 -$0.15 -$0.15 -$0.15
Q1 2026 1 -$0.11 -$0.11 -$0.11
Q2 2026 1 -$0.12 -$0.12 -$0.12
Q3 2026 1 -$0.12 -$0.12 -$0.12
Q4 2026 1 -$0.21 -$0.21 -$0.21

Inhibikase Therapeutics, Inc. Earnings Date And Information

Inhibikase Therapeutics, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-0.65 earnings per share for the quarter, missing analysts' consensus estimates of $-0.38 by $0.27. The company had revenue of 0 for the quarter and had revenue of 260,500 for the year. Inhibikase Therapeutics, Inc. has generated $-4 earnings per share over the last year ($-3.57 diluted earnings per share) and currently has a price-to-earnings ratio of -1.34. Inhibikase Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based on prior year's report dates.

Inhibikase Therapeutics, Inc. Earnings History by Quarter

Date Quarter Consensus Estimate Reported EPS Beat/Miss Revenue Estimate Actual Revenue
11/14/2024 Q3 2024 -$0.38 -$0.65 -0.27 $0 $0
08/14/2024 Q2 2024 -$0.58 -$0.66 -0.08 $0 $0
05/15/2024 Q1 2024 -$0.79 -$0.73 0.06 $0
03/27/2024 Q4 2023 -$0.78 -$0.68 0.1 $1
11/14/2023 Q3 2023 -$1.12 -$0.86 0.26 $79,569
08/14/2023 Q2 2023 -$0.92 -$1.11 -0.19 $116,410
05/15/2023 Q1 2023 -$0.90 -$0.87 0.03 $64,521
10/16/2023 Q4 2022 -$0.99 $123,440
11/14/2022 Q3 2022 -$0.18 -$1.06 -0.88 $200,000 $0
08/12/2022 Q2 2022 -$0.19 -$1.10 -0.91 $300,000 $6,552
05/16/2022 Q1 2022 -$0.17 -$1.10 -0.93 $46,031
03/31/2022 Q4 2021 -$0.17 -$1.20 -1.03 $1,944
11/15/2021 Q3 2021 -$0.14 -$1.07 -0.93 $200,000 $328,459
08/16/2021 Q2 2021 -$0.38 -$1.29 -0.91 $300,000 $1.36 M
05/17/2021 Q1 2021 -$1.57 $1.41 M
03/31/2021 Q4 2020 -$0.87 $698,468
09/29/2020 Q3 2020 -$0.49 $37,680
06/29/2020 Q2 2020 -$0.31 $219,585
03/30/2020 Q1 2020 -$0.40 $270,787
12/30/2019 Q4 2019 -$0.32 $240,276
 

Inhibikase Therapeutics, Inc. Earnings: FAQ's

When is Inhibikase Therapeutics, Inc.'s earnings date?

Inhibikase Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based off last year's report dates.

How can I listen to Inhibikase Therapeutics, Inc.'s earnings conference call?

The conference call for Inhibikase Therapeutics, Inc.'s latest earnings report can be listened to online.

How can I read Inhibikase Therapeutics, Inc.'s conference call transcript?

The conference call transcript for Inhibikase Therapeutics, Inc.'s latest earnings report can be read online.

How much revenue does Inhibikase Therapeutics, Inc. generate each year?

Inhibikase Therapeutics, Inc. (:IKT) has a recorded annual revenue of $260,500.

How much profit does Inhibikase Therapeutics, Inc. generate each year?

Inhibikase Therapeutics, Inc. (:IKT) has a recorded net income of $260,500. Inhibikase Therapeutics, Inc. has generated $-3.57 earnings per share over the last four quarters.

What is Inhibikase Therapeutics, Inc.'s price-to-earnings ratio?

Inhibikase Therapeutics, Inc. (:IKT) has a price-to-earnings ratio of -1.34 and price/earnings-to-growth ratio is -0.19.

Portfolio Sync
Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED